CD30/TNFRSF8, His & Avi, Human
CD30/TNFRSF8, His & Avi, Human

Immobilized CD30/TNFRSF8, His & Avi, Human, His Tag at 0.5 μg/ml (100 μL/well) on the plate. Dose response curve for Human CD30 Ligand, mFc Tag with the EC50 of 10.5 ng/ml determined by ELISA.

CD30/TNFRSF8, His & Avi, Human

The purity of CD30/TNFRSF8, His & Avi, Human is greater than 95% as determined by SEC-HPLC.

CD30/TNFRSF8, His & Avi, Human

CD30/TNFRSF8, His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

CD30/TNFRSF8, His & Avi, Human

The transmembrane receptor CD30 (TNFRSF8) and its ligand CD30L (CD153, TNFSF8) are members of the tumor necrosis factor (TNF) superfamily and display restricted expression in subpopulations of activated T-and B-cells in nonpathologic conditions. CD30 expression is upregulated in various hematological malignancies, including Reed-Sternberg cells in Hodgkin's disease (HD), anaplastic large cell lymphoma (ALCL) and subsets of Non-Hodgkin's lymphomas (NHLs).
Z04188
¥46,636.00

Ask us a question
Product Introduction
Species Human
Protein Construction
CD30/TNFRSF8 (Phe19-Lys379)
Accession # P28908-1		 His Avi
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE
> 95% as determined by HPLC
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Immobilized CD30/TNFRSF8, His & Avi, Human at 0.5μg/ml (100μl/well) on the plate can bind Human CD30 Ligand, mFc (IgG2a) Tag. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 41.3 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 68-95 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Examples
  • CD30/TNFRSF8, His & Avi, Human
    • CD30/TNFRSF8, His & Avi, Human

    Immobilized CD30/TNFRSF8, His & Avi, Human, His Tag at 0.5 μg/ml (100 μL/well) on the plate. Dose response curve for Human CD30 Ligand, mFc Tag with the EC50 of 10.5 ng/ml determined by ELISA.

  • CD30/TNFRSF8, His & Avi, Human
    • CD30/TNFRSF8, His & Avi, Human

    The purity of CD30/TNFRSF8, His & Avi, Human is greater than 95% as determined by SEC-HPLC.

  • CD30/TNFRSF8, His & Avi, Human
    • CD30/TNFRSF8, His & Avi, Human

    CD30/TNFRSF8, His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background The transmembrane receptor CD30 (TNFRSF8) and its ligand CD30L (CD153, TNFSF8) are members of the tumor necrosis factor (TNF) superfamily and display restricted expression in subpopulations of activated T-and B-cells in nonpathologic conditions. CD30 expression is upregulated in various hematological malignancies, including Reed-Sternberg cells in Hodgkin's disease (HD), anaplastic large cell lymphoma (ALCL) and subsets of Non-Hodgkin's lymphomas (NHLs).
Synonyms CD30; CD30KI-1; CD30L receptor; TNFRSF8; D1S166EKi-1; CD30KI-1

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.